Nirvana Life Sciences Inc.
NIRVF
$0.08
-$0.01-8.07%
OTC PK
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 30.99% | -147.17% | 77.84% | -116.27% | -23.16% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2,025.00% | -300.00% | -100.90% | 108.06% | -775.49% |
| Change in Net Operating Assets | 64.90% | 103.11% | -838.78% | 38.38% | 1,823.53% |
| Cash from Operations | 92.90% | 93.51% | -3,762.22% | 85.90% | -508.10% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -91.88% | 1,132.00% | -92.88% | 63.26% | 14.36% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -- | -- | -- |
| Cash from Financing | -89.64% | -93.61% | 532.51% | 263.58% | 9.42% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -342.86% | -- | -- | -191.57% | 1,116.48% |
| Net Change in Cash | -500.00% | 114.29% | -109.86% | 244.90% | -96.00% |